SAN CARLOS, Calif.-- October 14, 2026 -- Altay Therapeutics, Inc., a biotechnology company developing novel small molecule inhibitors of transcription factors, today announced the completion of a $37 million Series...
Arthur Klausner will be a panelist at the New York Biotechnology Association's Annual Meeting
News | 04. 17. 2006
